Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Tetsuhiro YoshinamiShigenori E NagaiMasaya HattoriTakuho OkamuraKenichi WatanabeTakahiro NakayamaHiroko MasudaMichiko TsuneizumiDaisuke TakabatakeMichiko HaraoHiroshi YoshinoNatsuko MoriHiroyuki YasojimaChiya OshiroMadoka IwaseMiki YamaguchiTakafumi SangaiNobuyoshi KosakaKentaro TajimaNorikazu MasudaPublished in: Breast cancer (Tokyo, Japan) (2024)
The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.